{"id":32036,"date":"2020-09-08T09:00:00","date_gmt":"2020-09-08T07:00:00","guid":{"rendered":"https:\/\/www.embl.org\/news\/?p=32036"},"modified":"2024-03-22T11:09:00","modified_gmt":"2024-03-22T10:09:00","slug":"achieving-personalised-therapeutics","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/","title":{"rendered":"Achieving personalised therapeutics"},"content":{"rendered":"\n<p>EMBL is part of a growing movement to achieve cell-based medicine in Europe.<\/p>\n\n\n\n<p>This week hundreds of leading scientists, clinicians, industry leaders, and policymakers from around Europe declared this a new age for cell-based medicine by publishing a perspective piece, \u2018Towards cell-based medicine in Europe\u2019, in the journal <em><a href=\"https:\/\/www.nature.com\/articles\/s41586-020-2715-9\" target=\"_blank\" rel=\"noreferrer noopener\">Nature<\/a><\/em>. They also published the <a href=\"https:\/\/lifetime-initiative.eu\/wp-content\/uploads\/2020\/08\/LifeTime-Strategic-Research-Agenda.pdf\">LifeTime Strategic Research Agenda<\/a>, a white paper that explains their suggested approach to turn to molecular and cellular biology for personalised medical treatments in the future.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/lifetime-fetflagship.eu\/\">LifeTime Initiative<\/a>, which includes EMBL Heidelberg and EMBL\u2019s European Bioinformatics Institute (EMBL-EBI), has developed a strategy to integrate breakthrough technologies to further develop personalised treatments for five major classes of disease: cancer, cardiovascular and metabolic disorders, chronic inflammation, infectious diseases, and neurological disorders.&nbsp;LifeTime is a consortium of more than 90 leading European research institutions, together with international advisers and over 80 supporting companies.<\/p>\n\n\n\n<p>Both publications elaborate on a roadmap for implementing cell-based medicine in Europe within the next decade. The roadmap explains how technology can be rapidly co-developed and transitioned into clinical settings to address key medical challenges. This requires close interactions between research institutions, hospitals, industry, and European infrastructures to deploy and analyse medical big data across European borders. LifeTime\u2019s vision advocates ethically responsible research that benefits all citizens, as outlined in an <a href=\"https:\/\/www.embopress.org\/doi\/10.15252\/embj.2020105725\"><em>EMBO Journal <\/em>commentary<\/a><em>.<\/em><\/p>\n\n\n\n<p>\u201cThe experimental techniques and technology platforms described in this Agenda have the potential to positively impact human health,\u201d says John Marioni, an EMBL-EBI Research Group Leader. \u201cHowever, to reach its full potential and ensure that cutting-edge machine learning is rapidly deployed to discover patterns associated with health status, the scientific community must share data. It\u2019s vital.\u201d<\/p>\n\n\n\n<p>Helen Parkinson, EMBL-EBI Team Leader for Samples, Phenotypes and Ontologies and Head of Molecular Archives, adds, \u201cOver the past 25 years, EMBL-EBI has not only developed computational methods that have enabled the uptake of these new technologies, but has also played a key role in ensuring that biological data can be quickly and easily shared and reused. We\u2019re excited to contribute our expertise in the context of LifeTime, ensuring the data generated is analysed using cutting-edge methods, and that these data can be securely and rapidly shared across Europe, according to the FAIR principles.\u201d<\/p>\n\n\n\n<p>The European Commission has established FAIR Data Principles as a set of uniform guiding principles to make data findable, accessible, interoperable, and reusable.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Navigating this roadmap to precision healthcare<\/h2>\n\n\n\n<p>The Agenda starts with the premise that human cells are programmed to follow certain developmental paths during which they acquire specific functions. When they deviate from their healthy course, the changes lead to disease.<\/p>\n\n\n\n<p>Scientists \u2013 and ultimately health care providers \u2013 can now understand molecular details and changes responsible for driving the onset and progression of diseases or the emergence of therapy resistance in each patient, LifeTime reports. Single-cell and imaging technologies allow scientists to observe and analyse cells individually and understand how cells \u2018make decisions\u2019.<\/p>\n\n\n\n<p>\u201cWe have brought together scientists, clinicians, computational scientists, engineers, mathematicians, physicists, social scientists, and more to understand mechanisms and find new means for intervention,\u201d says Nikolaus Rajewsky, Scientific Director of the Berlin Institute for Medical System Biology at the Max Delbr\u00fcck Center for Molecular Medicine, and LifeTime Initiative coordinator. \u201cCell-based medicine will diagnose diseases much earlier and intercept disorders before irreparable damage has occurred, allowing us to cure patients instead of treating their symptoms. LifeTime has a unique value proposition that promises to improve the European patient\u2019s health and the transformation of healthcare.\u201d&nbsp;<\/p>\n\n\n\n<p>Artificial intelligence and machine learning will identify complex patterns that can be reliably learned, and their output can be made interpretable for humans. This will be crucial for creating personalised disease models (organoids) for a patient that will guide the design of personalised therapeutic strategies and, at the same time, replace the need for animal models. This will substantially improve the outlook for many patients through timely treatment and more effective therapies, and has the potential to save billions of euros in disease-related costs in Europe, LifeTime reports.&nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<p>\u201cBy applying interceptive, cell-based medicine we will be able to considerably raise cure rates across many diseases. In the case of cancer, we can expect them to go up to 75% globally,\u201d says Genevi\u00e8ve Almouzni, co-coordinator of the LifeTime Initiative from Institut Curie in Paris. \u201cIt would save 6 billion euros in productivity gains across all cancer cases. Patients all over the world will be able to lead longer, healthier lives. The economic impact would be tremendous. For COVID-19, for instance, we could envisage significantly shortened ICU stays, which would help to lower costs. We have to invest in the necessary research now.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A decadal roadmap points the way to cell-based medicine for Europe<\/p>\n","protected":false},"author":100,"featured_media":32068,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3,17591],"tags":[125,807,4762,1000,556,4760],"embl_taxonomy":[9796,2906],"class_list":["post-32036","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lab-matters","category-science-technology","tag-big-data","tag-european-science","tag-lifetime-initiative","tag-molecular-medicine","tag-open-access","tag-precision-medicine","embl_taxonomy-embl-heidelberg","embl_taxonomy-embl-ebi"],"acf":{"featured":true,"show_featured_image":false,"color":"#563d82","link_color":"#fff","article_intro":"<p>A decadal roadmap points the way to cell-based medicine for Europe<\/p>\n","related_links":[{"link_description":"LifeTime - a visionary proposal for an EU Flagship","link_url":"https:\/\/www.embl.it\/aboutus\/communication_outreach\/media_relations\/2018\/0322_LifeTime_Flagship\/?_ga=2.1302577.1683613767.1599473571-1339211639.1594043510"},{"link_description":"Towards personalised medicine: one type of data is not enough","link_url":"https:\/\/www.embl.de\/aboutus\/communication_outreach\/media_relations\/2018\/0619_MSB_Stegle\/index.html?_ga=2.202573713.1683613767.1599473571-1339211639.1594043510"}],"article_sources":[{"source_description":"<p>Rajewsky N, <em>et al. <\/em><a href=\"https:\/\/www.nature.com\/articles\/s41586-020-2715-9\">LifeTime and improving European healthcare through cell-based interceptive medicine<\/a>. <em>Nature,<\/em> published online 7 September 2020. DOI: 10.1038\/s41586-020-2715-9<\/p>\n","source_link_url":"https:\/\/www.nature.com\/articles\/s41586-020-2715-9"},{"source_description":"<p>LifeTime Strategic Research Agenda<\/p>\n","source_link_url":"https:\/\/lifetime-initiative.eu\/wp-content\/uploads\/2020\/08\/LifeTime-Strategic-Research-Agenda.pdf"}],"in_this_article":false,"youtube_url":"","mp4_url":"","video_caption":"","press_contact":"None","translations":false,"vf_locked":false},"embl_taxonomy_terms":[{"uuid":"a:3:{i:0;s:36:\"b14d3f13-5670-44fb-8970-e54dfd9c921a\";i:1;s:36:\"89e00fee-87f4-482e-a801-4c3548bb6a58\";i:2;s:36:\"ab46b6d4-71d8-49f8-b2f4-b326d4c8ea4e\";}","parents":[],"name":["EMBL Heidelberg"],"slug":"embl-heidelberg","description":"Where &gt; All EMBL sites &gt; EMBL Heidelberg"},{"uuid":"a:3:{i:0;s:36:\"b14d3f13-5670-44fb-8970-e54dfd9c921a\";i:1;s:36:\"89e00fee-87f4-482e-a801-4c3548bb6a58\";i:2;s:36:\"a99d1a7c-ca83-4c00-ab61-d082d3e41ce3\";}","parents":[],"name":["EMBL-EBI"],"slug":"embl-ebi","description":"Where &gt; All EMBL sites &gt; EMBL-EBI"}],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Achieving personalised therapeutics | EMBL<\/title>\n<meta name=\"description\" content=\"The LifeTime Initiative, which includes EMBL Heidelberg and EMBL\u2019s European Bioinformatics Institute (EMBL-EBI), published a perspective piece, \u2018Towards cell-based medicine in Europe\u2019, in the journal Nature as well as the LifeTime Strategic Research Agenda, a white paper that explains their suggested approach to turn to molecular and cellular biology for personalised medical treatments in the future.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Achieving personalised therapeutics | EMBL\" \/>\n<meta property=\"og:description\" content=\"The LifeTime Initiative, which includes EMBL Heidelberg and EMBL\u2019s European Bioinformatics Institute (EMBL-EBI), published a perspective piece, \u2018Towards cell-based medicine in Europe\u2019, in the journal Nature as well as the LifeTime Strategic Research Agenda, a white paper that explains their suggested approach to turn to molecular and cellular biology for personalised medical treatments in the future.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-08T07:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-22T10:09:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/09\/Organoid-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ivy Kupec\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ivy Kupec\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/\"},\"author\":{\"name\":\"Ivy Kupec\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/427f2c9b624bc32ffa67d80414712274\"},\"headline\":\"Achieving personalised therapeutics\",\"datePublished\":\"2020-09-08T07:00:00+00:00\",\"dateModified\":\"2024-03-22T10:09:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/\"},\"wordCount\":776,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/09\/Organoid-3.jpg\",\"keywords\":[\"big data\",\"european science\",\"lifetime Initiative\",\"molecular medicine\",\"open access\",\"precision medicine\"],\"articleSection\":[\"Lab Matters\",\"Science &amp; Technology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/\",\"url\":\"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/\",\"name\":\"Achieving personalised therapeutics | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/09\/Organoid-3.jpg\",\"datePublished\":\"2020-09-08T07:00:00+00:00\",\"dateModified\":\"2024-03-22T10:09:00+00:00\",\"description\":\"The LifeTime Initiative, which includes EMBL Heidelberg and EMBL\u2019s European Bioinformatics Institute (EMBL-EBI), published a perspective piece, \u2018Towards cell-based medicine in Europe\u2019, in the journal Nature as well as the LifeTime Strategic Research Agenda, a white paper that explains their suggested approach to turn to molecular and cellular biology for personalised medical treatments in the future.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/09\/Organoid-3.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/09\/Organoid-3.jpg\",\"width\":1000,\"height\":600,\"caption\":\"Personalised medicine will progress due to important advances like the increasing use of organoids. Here, sections of cerebral brain organoids have been derived from pluripotent stem cells. Credit: \u00a9Agnieszka Rybak-Wolf, MDC\/LifeTime\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/427f2c9b624bc32ffa67d80414712274\",\"name\":\"Ivy Kupec\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1abc86f00519d61bc0f2793ed624175c2d7ad829fb5b60e1c3b99a973ac351a6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1abc86f00519d61bc0f2793ed624175c2d7ad829fb5b60e1c3b99a973ac351a6?s=96&d=mm&r=g\",\"caption\":\"Ivy Kupec\"},\"url\":\"https:\/\/www.embl.org\/news\/author\/ivy-kupecembl-de\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Achieving personalised therapeutics | EMBL","description":"The LifeTime Initiative, which includes EMBL Heidelberg and EMBL\u2019s European Bioinformatics Institute (EMBL-EBI), published a perspective piece, \u2018Towards cell-based medicine in Europe\u2019, in the journal Nature as well as the LifeTime Strategic Research Agenda, a white paper that explains their suggested approach to turn to molecular and cellular biology for personalised medical treatments in the future.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Achieving personalised therapeutics | EMBL","og_description":"The LifeTime Initiative, which includes EMBL Heidelberg and EMBL\u2019s European Bioinformatics Institute (EMBL-EBI), published a perspective piece, \u2018Towards cell-based medicine in Europe\u2019, in the journal Nature as well as the LifeTime Strategic Research Agenda, a white paper that explains their suggested approach to turn to molecular and cellular biology for personalised medical treatments in the future.","og_url":"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2020-09-08T07:00:00+00:00","article_modified_time":"2024-03-22T10:09:00+00:00","og_image":[{"width":1000,"height":600,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/09\/Organoid-3.jpg","type":"image\/jpeg"}],"author":"Ivy Kupec","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Ivy Kupec","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/"},"author":{"name":"Ivy Kupec","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/427f2c9b624bc32ffa67d80414712274"},"headline":"Achieving personalised therapeutics","datePublished":"2020-09-08T07:00:00+00:00","dateModified":"2024-03-22T10:09:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/"},"wordCount":776,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/09\/Organoid-3.jpg","keywords":["big data","european science","lifetime Initiative","molecular medicine","open access","precision medicine"],"articleSection":["Lab Matters","Science &amp; Technology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/","url":"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/","name":"Achieving personalised therapeutics | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/09\/Organoid-3.jpg","datePublished":"2020-09-08T07:00:00+00:00","dateModified":"2024-03-22T10:09:00+00:00","description":"The LifeTime Initiative, which includes EMBL Heidelberg and EMBL\u2019s European Bioinformatics Institute (EMBL-EBI), published a perspective piece, \u2018Towards cell-based medicine in Europe\u2019, in the journal Nature as well as the LifeTime Strategic Research Agenda, a white paper that explains their suggested approach to turn to molecular and cellular biology for personalised medical treatments in the future.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/lab-matters\/achieving-personalised-therapeutics\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/09\/Organoid-3.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/09\/Organoid-3.jpg","width":1000,"height":600,"caption":"Personalised medicine will progress due to important advances like the increasing use of organoids. Here, sections of cerebral brain organoids have been derived from pluripotent stem cells. Credit: \u00a9Agnieszka Rybak-Wolf, MDC\/LifeTime"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/427f2c9b624bc32ffa67d80414712274","name":"Ivy Kupec","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1abc86f00519d61bc0f2793ed624175c2d7ad829fb5b60e1c3b99a973ac351a6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1abc86f00519d61bc0f2793ed624175c2d7ad829fb5b60e1c3b99a973ac351a6?s=96&d=mm&r=g","caption":"Ivy Kupec"},"url":"https:\/\/www.embl.org\/news\/author\/ivy-kupecembl-de\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/09\/Organoid-3.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/09\/Organoid-3.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/32036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/100"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=32036"}],"version-history":[{"count":19,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/32036\/revisions"}],"predecessor-version":[{"id":32144,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/32036\/revisions\/32144"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/32068"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=32036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=32036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=32036"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=32036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}